MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, EDIT had $13,897K increase in cash & cash equivalents over the period. -$165,848K in free cash flow.

Cash Flow Overview

Change in Cash
$13,897K
Free Cash flow
-$165,848K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Proceeds from offering of common...
    • Right-of-use assets
    • Others
Negative Cash Flow Breakdown
    • Deferred revenue
    • Accrued expenses
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Net loss
-160,060
Stock-based compensation expense
10,000
Depreciation
5,277
Loss on disposal of fixed assets
-2,193
Net accretion of discounts on marketable securities
902
Interest related to sale of future revenues
6,171
Impairment of held for sale assets
3,758
Other non-cash items, net
449
Accounts receivable
-1,090
Prepaid expenses and other current assets
-1,062
Right-of-use assets
-11,584
Other non-current assets
-1,040
Accounts payable
-2,888
Accrued expenses
-13,184
Accrued interest on sale of future revenues
-2,128
Deferred revenue
-15,916
Operating lease liabilities
-12,081
Other non-current liabilities
192
Net cash used in operating activities
-165,241
Purchases of property and equipment
607
Proceeds from the sale of equipment
269
Purchases of marketable securities
0
Proceeds from maturities of marketable securities
139,006
Net cash provided by investing activities
138,668
Repayment on sale of future revenues
2,872
Proceeds from offering of common stock, net of issuance costs
42,848
Proceeds from sale of future revenues, net
0
Proceeds from exercise of stock options
70
Issuance of common stock under benefit plans
424
Net cash provided by financing activities
40,470
Net increase (decrease) in cash, cash equivalents, and restricted cash
13,897
Cash, cash equivalents, and restricted cash, beginning of period
135,418
Cash, cash equivalents, and restricted cash, end of period
149,315
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$139,006K Proceeds from offering ofcommon stock, net of...$42,848K Proceeds from the sale ofequipment$269K Issuance of common stockunder benefit plans$424K Proceeds from exercise ofstock options$70K Net cash provided byinvesting activities$138,668K Net cash provided byfinancing activities$40,470K Canceled cashflow$607K Canceled cashflow$2,872K Net increase(decrease) in cash, cash...$13,897K Canceled cashflow$165,241K Purchases of property andequipment$607K Right-of-use assets-$11,584K Stock-based compensationexpense$10,000K Interest related to saleof future revenues$6,171K Depreciation$5,277K Impairment of held for saleassets$3,758K Loss on disposal offixed assets-$2,193K Accounts receivable-$1,090K Prepaid expenses andother current assets-$1,062K Other non-currentassets-$1,040K Other non-currentliabilities$192K Repayment on sale of futurerevenues$2,872K Net cash used inoperating activities-$165,241K Canceled cashflow$42,367K Net loss-$160,060K Deferred revenue-$15,916K Accrued expenses-$13,184K Operating leaseliabilities-$12,081K Accounts payable-$2,888K Accrued interest on saleof future revenues-$2,128K Net accretion ofdiscounts on marketable...$902K Other non-cash items,net$449K

Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT)